Department of Medical Radiation Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Medical Physics, County Hospital Ryhov, Jönköping, Sweden.
Acta Oncol. 2022 Aug;61(8):1004-1011. doi: 10.1080/0284186X.2022.2092420. Epub 2022 Jul 29.
Respiratory-induced lung tumor motion may affect the delivered dose in stereotactic body radiation therapy (SBRT). Previous studies are often based on phantom studies for one specific treatment technique. In this study, the dosimetric effect of tumor motion was quantified in real patient geometries for different modulated treatments and tumor motion amplitudes for lung-SBRT.
A simulation method using deformable image registrations and 4-dimensional computed tomographies (4DCT) was developed to assess the dosimetric effects of tumor motion. The method was evaluated with ionization chamber and Gafchromic film measurements in a thorax phantom and used to simulate the effect for 15 patients with lung tumors moving 7.3-27.4 mm. Four treatment plans with different complexities were created for each patient and the motion-induced dosimetric effect to the gross tumor volume (GTV) was simulated. The difference between the planned dose to the static tumor and the simulated delivered dose to the moving tumor was quantified for the near minimum (D), near maximum (D) and mean dose (D) to the GTV as well as the largest observed local difference within the GTV (Max).
No correlation was found between the dose differences and the tumor motion amplitude or plan complexity. However, the largest deviations were observed for tumors moving >15.0 mm. The simulated delivered dose was within 2.5% from the planned dose for D (tumors moving <15 mm) and within 3.3% (tumors moving >15 mm). The corresponding values were 1.7% vs. 6.4% (D); 1.7% vs. 2.4% (D) and 8.9% vs. 35.2% (Max). Using less complex treatment techniques minimized Max for tumors moving >15.0 mm.
The dosimetric effects of respiratory-induced motion during lung SBRT are patient and plan specific. The magnitude of the dosimetric effect cannot be assessed solely based upon tumor motion amplitude or plan complexity.
呼吸引起的肺部肿瘤运动可能会影响立体定向体部放射治疗(SBRT)中的剂量分布。以往的研究通常基于特定治疗技术的体模研究。在这项研究中,我们在真实患者的解剖结构中量化了肿瘤运动的剂量学效应,以及不同调强治疗和肿瘤运动幅度对肺部 SBRT 的影响。
我们开发了一种使用形变图像配准和 4 维 CT(4DCT)的模拟方法,用于评估肿瘤运动的剂量学效应。该方法通过在体模中的电离室和 Gafchromic 胶片测量进行了评估,并用于模拟 15 例肺部肿瘤运动幅度为 7.3-27.4mm 的患者的效应。为每位患者创建了 4 种不同复杂性的治疗计划,并模拟了运动对大体肿瘤体积(GTV)的剂量学影响。静态肿瘤的计划剂量与运动肿瘤的模拟剂量之间的差异,被量化为 GTV 的近最小剂量(D)、近最大剂量(D)和平均剂量(D)以及 GTV 内最大观察到的局部差异(Max)。
我们没有发现剂量差异与肿瘤运动幅度或计划复杂性之间存在相关性。然而,最大的偏差发生在肿瘤运动幅度>15mm 的情况下。对于 D(肿瘤运动幅度<15mm),模拟的剂量分布与计划剂量相差在 2.5%以内;对于 D(肿瘤运动幅度>15mm),相差在 3.3%以内。相应的数值分别为 1.7%对 6.4%(D);1.7%对 2.4%(D)和 8.9%对 35.2%(Max)。使用更简单的治疗技术可以使肿瘤运动幅度>15mm 时的 Max 最小化。
肺部 SBRT 期间呼吸引起的运动的剂量学效应是患者和计划特异性的。剂量学效应的幅度不能仅仅根据肿瘤运动幅度或计划复杂性来评估。